Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome

Daru

Volumn 17, Issue 3, 2009, Pages 163-167

  Khalili, H ^a   Dashti Khavidaki, S ^a   Rasoolinejad, M ^b   Rezaie, L ^a   Etminani, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug reactions; Anti tuberculosis; Hepatotoxicity; Risk factors

Indexed keywords

ETHAMBUTOL; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; IRAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SIDE EFFECT; TUBERCULOSIS;

EID: 70350340310     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brewer TF, Heymann SJ .To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health, 2004; 58:822-825.
2. Forget EJ, Menzies D. Adverse reactions to first-line anti-tuberculosis drugs. Expert Opin Drug Saf, 2006;5:231-249. (Pubitemid 43379622)
3. Hussain Z, Kar P, Hussain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol, 2003;41:1226-1232. (Pubitemid 37379303)
4. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet, 2003; 362: 887-899.
5. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle, 1978; 59: 13-32.
6. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, van der Ven AJ, and Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol, 2008; 23: 192-202. (Pubitemid 351257678)
7. Breen RMA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax, 2006; 61:791-794. (Pubitemid 44369404)
8. World Health Organization Global Tuberculosis Programme. Treatment of Tuberculosis: Guidelines for National Programmes,3rd edn. (WHO/CDS/TUBERCULOSIS/ 2003.13). Geneva: World Health Organization, 2003.
9. World Health Organization. Uppsala Monitoring Center. Safety monitoring of medicinal products, guidelines for setting up and running pharmacovigilance center, Geneva, 1996.
10. Meyboom RHB, Hekster YA, Egberts ACG, Gribnau FWJ, Edwards IR. Causal or casual? The role of causality assessment in Pharmacovigilance. Drug Saf, 1997; 16: 374-389.
11. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med, 2006; 174:935-952 (Pubitemid 44564795)
12. Kaplowitz N. Drug-induced liver injury. Clin Infec Dis, 2004; 38 (suppl 2): S44-8.
13. World Health Organization. International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology. Uppsala: WHO Collaborating Center for International Drug Monitoring, 1992.
14. Gangadharam PRG. Isoniazid, rifampin and hepatotoxicity. Am Rev Respir Dis, 1986; 133: 963-965.
15. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment. Pharmacol Res, 2005;51:353-358 (Pubitemid 40430809)
16. Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf, 2007 Oct;16:1104-1110
17. Steele M, Burk RF, Desprez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 1991; 99:465-471.
18. Tahaoglu K, Atac G, Sevim T, Tarun T, Yazicioglu O, Horzum G, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis, 2001; 5: 65-69.
19. Teleman MD, Chee CBE, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general program condition in Singapore. Int J Tuberc Lung Dis, 2002; 6: 699-705. (Pubitemid 34832150)
20. Yew WW, Leung CC. Anti-tuberculosis drugs and hepatotoxicity. Respirology, 2006; 11: 699-707.
21. Durand F, Jebrac G, Passayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Drug Safety, 1996;15:394-405.
22. Wing wai YEW, Chi Chiu LEUNG. Anti-tuberculosis drugs and hepatotoxicity. Respirology, 2006;11: 699-707.
23. Chang CY, Schiano TD. Drug Hepatotoxicity. Alimen Pharmacol Ther, 2007; 25:1135-1151.
24. Khalili H, Dashti-khavidaki S, Sajadi S, Hajiabolbaghi M. Assessment of adherence to tuberculosis drug regimen. DARU, 2008; 16: 47-50. (Pubitemid 351270444)